Key result
Mutations eliminating potential glycosylation sites in the Hepatitis E virus capsid protein prevented the formation of infectious virus particles and abolished infectivity in rhesus macaques.
Mutations in potential glycosylation sites of the Hepatitis E virus capsid protein prevent the formation of infectious virus particles by perturbing protein structure rather than eliminating glycosylation.
Answers are grounded in this paper and cite their sources.
Animal data identify HEV capsid as potential antiviral target; leaves open human translation and mechanism-based interventions.
Hepatitis E virus is a nonenveloped RNA virus. However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture. In order to determine whether these unexpected observations were biologically relevant or were artifacts of overexpression, we analyzed capsid protein produced during a normal viral replication cycle. In vitro transcripts from an infectious cDNA clone mutated to eliminate potential glycosylation sites were transfected into cultured Huh-7 cells and into the livers of rhesus macaques. The mutations did not detectably affect genome replication or capsid protein synthesis in cell culture. However, none of the mutants infected rhesus macaques. Velocity sedimentation analyses of transfected cell lysates revealed that mutation of the first two glycosylation sites prevented virion assembly, whereas mutation of the third site permitted particle formation and RNA encapsidation, but the particles were not infectious. However, conservative mutations that did not destroy glycosylation motifs also prevented infection. Overall, the data suggested that the mutations were lethal because they perturbed protein structure rather than because they eliminated glycosylation.
No takes yet. Share an insight, caveat, or question.
Graff et al. (2007) studied Hepatitis E Virus (HEV) infection. Mutations in potential glycosylation sites of HEV capsid protein (ORF2) vs. Wild-type HEV (Sar-55) was evaluated on Infectivity (seroconversion in macaques and infected cell foci in vitro). Mutations eliminating potential glycosylation sites in the Hepatitis E virus capsid protein prevented the formation of infectious virus particles and abolished infectivity in rhesus macaques.
Synapse has enriched 10 related papers. Consider them for comparative context: